Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02970292 · ClinicalTrials.gov registry record · Phase 3

Efficacy and Safety of Adjunctive Pimavanserin for the Treatment of Schizophrenia (ENHANCE-1)

A Phase 3 study of Schizophrenia, sponsored by ACADIA Pharmaceuticals.

Completed
Registry status
Phase 3
Development phase
396
Enrollment target
20
Study locations

NCT02970292 is a Phase 3 study of Schizophrenia that has completed, run by ACADIA Pharmaceuticals. The registered enrollment target is 396 participants, above the 218-participant average among 315 other Schizophrenia trials with a reported enrollment target (82% higher). The trial reports 20 study locations across 6 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02970292, a Phase 3 study of Schizophrenia, has completed, sponsored by ACADIA Pharmaceuticals.

COMPLETED
Registry status
Phase 3
Development phase
396 participants
Enrollment target
20
Study locations

Study Summary

To evaluate the efficacy and safety of adjunctive pimavanserin compared with adjunctive placebo in the treatment of schizophrenia

Conditions Studied

Schizophrenia

Interventions

  • DRUG Placebo
  • DRUG Pimavanserin

Study Locations (20)

California

  • - Bellflower
  • - Cerritos
  • - Culver City
  • - Lemon Grove
  • - Long Beach
  • - San Diego
  • - San Diego
  • - Santa Ana
  • - Torrance

Florida

  • - Boca Raton
  • - Lauderhill
  • - Miami

Illinois

  • - Chicago
  • - Chicago
  • - Hoffman Estates

Arkansas

  • - Little Rock
  • - Rogers

Georgia

  • - Atlanta
  • - Atlanta

Arizona

  • - Phoenix

Trial Details

FieldValue
Enrollment Target 396 participants
Start Date 2016-10-26
Est. Completion 2019-06-25
Phase Phase 3

Sponsor

ACADIA Pharmaceuticals

35 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02970292

The ClinicalTrials.gov registry entry for NCT02970292 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 396 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 218-participant average among 315 other Schizophrenia trials with a reported enrollment target (82% higher). The listed sponsor is ACADIA Pharmaceuticals, which has 35 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Schizophrenia appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT02970292 reports 20 study locations spanning 6 distinct geographic areas - top geographies include California, Florida, Illinois.

Frequently Asked Questions

What is clinical trial NCT02970292 about?

NCT02970292 is a clinical study titled "Efficacy and Safety of Adjunctive Pimavanserin for the Treatment of Schizophrenia (ENHANCE-1)". To evaluate the efficacy and safety of adjunctive pimavanserin compared with adjunctive placebo in the treatment of schizophrenia

What is the current status of trial NCT02970292?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 396 participants. The study started on 2016-10-26. Estimated completion is 2019-06-25.

What conditions does trial NCT02970292 study?

This clinical trial studies the following conditions: Schizophrenia.

What interventions are being tested in trial NCT02970292?

The interventions under investigation include: Placebo (DRUG), Pimavanserin (DRUG).

Who is sponsoring clinical trial NCT02970292?

This trial is sponsored by ACADIA Pharmaceuticals, which has 35 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02970292 being conducted?

This trial has 20 study locations across Arizona, Arkansas, California, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Schizophrenia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Schizophrenia

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.